Stocks Health care VMD
NASDAQ · Health careViemed Healthcare, Inc. (VMD)
Viemed Healthcare, Inc. brought in $310.4M of revenue over the twelve months to September 30, 2026, up 21.8% from a year earlier. Net income was $15.6M, a net margin of 5.0%. Operating cash flow minus capital spending left $11.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $9.7M in cash against $5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Viemed Healthcare, Inc.
- Net worth
- Viemed Healthcare, Inc. has a market value (market cap) of $340.9M at the latest share price, and shareholders' equity of $150.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $270.3M (+20.5% year on year), with net income of $14.9M. Over the 12 months to September 30, 2026: revenue $310.4M, net income $15.6M.
- Cash flow
- In fiscal 2025 operations brought in $51.9M of cash; after $40M of capital spending, free cash flow was $11.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Viemed Healthcare, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Viemed Healthcare, Inc. does
Viemed Healthcare, Inc. is registered with the SEC under industry code SIC 8090 (Services-Misc Health & Allied Services, NEC). Its shares trade on NASDAQ under the ticker VMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $270.3M | $14.9M | $0.37 | $11.9M |
| 2024 | $224.3M | $11.3M | $0.28 | $1.3M |
| 2023 | $183M | $10.2M | $0.25 | $19.1M |
| 2022 | $138.8M | $6.2M | $0.16 | $4.9M |
| 2021 | $117.1M | $9.1M | $0.22 | $2.8M |
| 2020 | $131.3M | $31.5M | $0.78 | $22.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VMD ranks in Health care
Latest SEC filings
What Viemed Healthcare, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 12% to $80.7M versus the same quarter last year; diluted EPS $0.11 versus $0.09.
- November 4, 2026
- September 24, 2026Activist stake changed SCHEDULE 13D/A
- August 20, 2026
- August 5, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 24% to $78.1M versus the same quarter last year; diluted EPS $0.07 versus $0.08.
- August 3, 2026
- July 24, 2026Passive stake changed SCHEDULE 13G/A
- June 4, 2026
- June 2, 2026
What is VMD worth? A DCF from its reported cash flow
Insider trades
What the people running Viemed Healthcare, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 10 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Dobbs Randy E.Director | Exercised options | 16,763 | - |
| August 19, 2026 | Dobbs Randy E.Director | Exercised options | 4,191 | - |
| August 19, 2026 | Dobbs Randy E.Director | Other change | 4,191 | $37.5K |
| August 19, 2026 | Smokoff TimothyDirector | Exercised options | 15,029 | - |
| August 19, 2026 | Smokoff TimothyDirector | Exercised options | 3,757 | - |
| August 19, 2026 | Smokoff TimothyDirector | Other change | 3,757 | $33.6K |
| August 19, 2026 | Kaushal NitinDirector | Exercised options | 18,786 | - |
| August 19, 2026 | Heltz SabrinaDirector | Exercised options | 15,029 | - |
Who owns VMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Thrivent Financial For Lutherans13G, passive | 6.8% | April 29, 2025 |
| BlackRock Portfolio Management LLC13G, passive | 6.4% | July 15, 2025 |
| Michael Moore13D, may seek influence with 1 related filers | 5.9% | September 24, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 167 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,788,307 | +165,745 |
| Forager Capital Management, LLC | 2,141,184 | -684,687 |
| Vanguard Capital Management LLC | 1,321,676 | +18,292 |
| Nantahala Capital Management, LLC | 1,264,890 | +381,107 |
| Goldman Sachs Group Inc | 1,222,534 | -199,100 |
| First Eagle Investment Management, LLC | 1,070,314 | +540,657 |
| Ameriprise Financial Inc | 1,006,195 | +107,876 |
| Geode Capital Management, LLC | 973,744 | +194,222 |
| Raffles Associates LP | 807,382 | +393,691 |
| Arrowstreet Capital, Limited Partnership | 786,269 | +75,083 |
| State Street Corp | 762,097 | +19,138 |
| Panagora Asset Management Inc | 538,625 | +66,528 |
| Punch & Associates Investment Management, Inc. | 533,466 | -3,895 |
| Two Sigma Investments, LP | 438,851 | +25,457 |
| Renaissance Technologies LLC | 425,900 | -16,300 |
| Creative Planning | 360,356 | +139,954 |
| Tocqueville Asset Management L.P. | 342,100 | -130,000 |
| Martin & Co Inc | 340,771 | +67,770 |
| Bard Associates Inc | 339,672 | -269 |
| Morgan Stanley | 300,410 | -24,128 |
Insiders
11 insiders reported holding 3,321,788 shares in total, about $29.7M at the last price.
| Holder | Shares |
|---|---|
| Moore MichaelPresident | 1,774,9021,585,812 held indirectly |
| Zehnder William ToddChief Operating Officer, Director | 390,309 |
| Hoyt CaseyChief Executive Officer, Director | 350,464 |
| Kaushal NitinDirector | 161,361 |
| Dobbs Randy E.Director | 142,253 |
| Fitzgerald TraeChief Financial Officer | 105,638 |
| Cambre JeromeVice President of Sales | 104,088 |
| Smokoff TimothyDirector | 90,547 |
| Heltz SabrinaDirector | 82,520 |
| Frazier WilliamChief Medical Officer, Director | 73,214 |
Questions about VMD
What does Viemed Healthcare, Inc. do?
Viemed Healthcare, Inc. is a company in the Health care sector, listed on NASDAQ as VMD. Its shares trade on NASDAQ under the ticker VMD.
What is Viemed Healthcare, Inc.'s net worth?
Viemed Healthcare, Inc. has a market value (market cap) of $340.9M at the latest share price, and shareholders' equity of $150.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Viemed Healthcare, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $15.6M on revenue of $310.4M, a net margin of 5.0%.
How much revenue does Viemed Healthcare, Inc. make?
Over the twelve months to September 30, 2026 Viemed Healthcare, Inc. reported revenue of $310.4M. That is 21.8% more than a year earlier.
When did Viemed Healthcare, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Viemed Healthcare, Inc.'s next earnings report?
Viemed Healthcare, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VMD with
Follow VMD
Get an email when Viemed Healthcare, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Viemed Healthcare, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.